



28 October 2021

Four patents filed following groundbreaking results in study of gynecological cancers

HIGHLIGHTS

- Four patents filed with USPTO following groundbreaking results in a clinical set-up study conducted with the University of Newcastle
- Ecofibre is focused on addressing the significant need for new treatment and management options for gynecological diseases
- The Company continues to invest in its broader clinical research portfolio in the US and Australia to differentiate its products and professionalise the hemp-derived CBD industry

Ecofibre Limited (Ecofibre, Company) (ASX: EOF, ADR: EOFBY) has filed four patent applications with the US Patent and Trademark Office (USPTO) following groundbreaking data from its pain study being conducted with the University of Newcastle.

Groundbreaking results from the study


Ecofibre's research partnership with the University of Newcastle was launched in early 2021 (Newcastle Pain Study). Despite the challenges of COVID-19, 31 patients have now participated in the study in a period of only seven months. All patients have responded positively to Ananda's proprietary CBD formulation, as illustrated by the photos below which represent a sample of data collected.

The groundbreaking results from this clinical study using patient-derived organoids have led to four patent filings. The photos below demonstrate that diseased cells of varying gynecological diseases (CONTROL) were completely eradicated upon treatment with Ananda Health's proprietary formulation (CBD Tx).







Patient A



Patient B



Patient C



Successful responses shown above are consistent for all (31) patients to date.



Investing in new treatment and management options for gynecological diseases

Dr. Alex Capano, Chief Science Officer for Ecofibre states, "Women face a host of gynecological disorders for which there is currently no adequate method of treatment. Various forms of pelvic pain affect over 80% of women and are associated with infertility and poor health and socioeconomic outcomes."

"Gynecological cancers account for over 15% of cancers diagnosed in women globally. They are frequently diagnosed in late stages, considerably aggressive, difficult to treat and often result in metastatic disease. The five-year survival rates for certain gynecological cancers range from 17-39%. The need for improved therapeutic options is clear," states Dr. Capano.

Professor Pradeep Tanwar, the NHMRC RD Wright Biomedical Fellow at the University of Newcastle states, "Our work with Ecofibre addresses a pressing unmet clinical need to provide new treatment and management options for gynecological diseases. Women with metastatic gynecological cancers have limited treatment options. The 5-year survival rate of many gynecological cancers is lower than other solid cancers and has not significantly improved in the last 20 years. We are excited about these initial results and now developing strong scientific rationale for the clinical application of CBD for various gynaecological disorders."

Ecofibre continues to invest in its clinical research program

Ecofibre continues to focus on developing new clinical solutions using CBD. "We laid the groundwork with the FDA in early 2020 when we received our first IND. Since then, our research portfolio has expanded considerably" says Ecofibre CEO Eric Wang.

Study focus	Research Institution	Patient Population	Location	Type / Phase	Status
Opioid Reduction	Murphy Clinic	Chronic opioid	Louisville, KY	Prospective cohort study	Complete - published 2019 in Journal of Postgraduate Medicine
Pain (neuropathic)	Lankenau Institute for Medical Research	Breast, colon and ovarian cancer	Philadelphia, PA	Phase 2	Enrollment underway (FDA authorized - IND)
Sleep and anxiety	Eastern Virginia Medical School	Dementia	Norfolk, VA	Phase 2	Enrollment underway (FDA authorized - IND)
Sleep	Southern Cross University	Healthy population	Australia (4 sites)	Phase 2b	Enrollment underway
Pain (endometriosis)	University of Newcastle	Endometriosis	Newcastle, Australia	Avatar study	Initial phase underway, patents filed
Addiction	University of Colorado	Alcohol use disorder	Boulder, CO	Phase 2	Enrollment underway (FDA authorized - IND)
Cognitive decline	University of Colorado	Adults, no dementia	Boulder, CO	Phase 2	Enrollment underway [FDA authorized] - IND

Mr Wang continued "The FDA has now authorised four INDs using Ecofibre's CBD products in clinical trials, half of which are funded externally by NIH entities. Academic researchers recognise the value of working with a company with established INDs, reducing barriers to study approval and accelerating scientific discovery."

"Our broader research goal is to provide healthcare professionals and patients with quality data on the safety and efficacy of hemp extract. Ecofibre will continue to expand its collaboration with the University of Newcastle and Professor Tanwar, and the Company will update the market when the next stage of research plans is finalised", said Wang.

Additional Background

Professor Pradeep Tanwar

Professor Pradeep Tanwar is an NHMRC RD Wright Biomedical Fellow within the School of Biomedical Science at the University of Newcastle.

He is an outstanding researcher who has established himself as a national and international leader in the field of gynecological cancers. In 2012, he relocated from Harvard Medical School to Newcastle and established the Global Centre for Gynecological Diseases (GCGD) by bringing together various researchers and clinicians working in different local hospitals and the university. Therefore, as a collective, GCGD now has the experience and clinical trials infrastructure in place required for translating project outcomes to patient treatment. The excellence of his research has been recognized by the award of three consecutive fellowships by NHMRC, ARC, and Cancer Institute NSW, >\$9 million in funding support, and an exceptional publication record, including senior author papers in high-quality international journals. His papers are most often published in the top-ranking journals specific to the field of either Cancer Biology or Reproductive Biology, including Nature Genetics, Cell Stem Cell, PNAS x 4, Cell Reports x 2, Cancer Research. Significantly, several of his articles have received independent commentaries, cover page editions and are widely covered by the media. He also receives regular invitations to deliver high-profile plenary/invited talks at international and national conferences.

Dr. Alex Capano

Alex Capano, DNP, CRNP, FNP-BC, is the Chief Science Officer of Ecofibre Limited, the global leader in hemp technologies that provides innovation solutions to address emerging health and resource sustainability issues.

At Ecofibre, Dr. Capano champions the company's multi-million-dollar commitment to research to advance the clinical evidence of hemp extract. Ecofibre was the first hemp company to receive IND authorization from the FDA for research. Partnering with leading healthcare and academic institutions, Dr. Capano is currently researching CBD's effects on CIPN, sleep, anxiety, addiction, gynecological disorders, certain cancers, and cognitive decline. Dr. Capano's recent clinical trial concluded that CBD hemp extract could reduce opioid use and improve quality of life indicators in chronic pain patients.

Dr. Capano earned her DNP at Thomas Jefferson University in Philadelphia, Pennsylvania, where she graduated Summa Cum Laude and was awarded the Sandra Festa Ryan award for Outstanding Creativity and Innovation. She was the first doctoral candidate of any discipline who focused on cannabinoid science under the guidance of the Lambert Center for the Study of Medicinal Cannabis and Hemp. Dr. Capano also holds a BSN and an MSN from the University of Pennsylvania, and a BS from the University of Miami.



Investor Relations and Media please contact:

Jonathan Brown, Company Secretary, Ecofibre Limited
Level 12, 680 George Street, Sydney NSW 2000
investor-relations@ecofibre.com

About Ecofibre

Ecofibre is a provider of hemp products in the United States and Australia.

In the United States, the Company produces nutraceutical products for human and pet consumption, as well as topical creams and salves. See www.anandahemp.com and www.anandaprofessional.com. The Company also supplies its leading Ananda Hemp CBD products to Australians via the SAS B program. See www.anandahemp.com.au.

In Australia, the Company grows and produces hemp food products including protein powders, de-hulled hemp seed and hemp oil. See www.anandafood.com.

The Company also develops and produces innovative hemp-based textile products in the United States. See www.hempblack.com.

The Company owns or controls key parts of the value chain in each business, from breeding, growing and production to sales and marketing. Our value proposition to customers is built on strong brands and quality products.

Authorisation

This document is authorised to be given to the Australian Securities Exchange (ASX) by the Chairman of the Board of the Company.

